AstraZeneca defends vaccine as more countries suspend its use
The company says a new safety review of its COVID-19 vaccine shows no increased blood clot risk
AstraZeneca says it’s conducted a review of 17 million patients which shows no evidence its COVID-19 vaccine increases the risk of pulmonary embolism or DVT.
A dozen countries partially or totally suspended use of the vaccine last week after reports from Austria and Denmark of patients suffering blood clots shortly after vaccination.
